Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC

Sylvain Garciaz,Mickael Loschi,Adèle de Masson,Lucie Biard,Mélanie Mercier,Cécile Tomowiak,Jeremy Delage,Hélène Labussière-Wallet,David Sibon,Ophélie Cassuto,Cécile Borel,Jérôme Cornillon,Stanislas Nimubona,Amandine Charbonnier,Pauline Brice,Gérard Socié,Reda Bouabdallah,Régis Peffault de Latour,Flore Sicre de Fontbrune

Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC

2019

Sylvain Garciaz
Mickael Loschi
Adèle de Masson
Lucie Biard
Mélanie Mercier
Cécile Tomowiak
Jeremy Delage
Hélène Labussière-Wallet
David Sibon
Ophélie Cassuto
Cécile Borel
Jérôme Cornillon
Stanislas Nimubona
Amandine Charbonnier
Pauline Brice
Gérard Socié
Reda Bouabdallah
Régis Peffault de Latour
Flore Sicre de Fontbrune

Brentuximab vedotin (BV) is an antibody–drug conjugate (ADC) composed of a CD30-directed monoclonal antibody covalently linked to the anti-microtubule agent monomethyl auristatin E (MMAE). Binding ...

Keywords:

Immunology
Refractory
Oncology
Brentuximab vedotin
CD30 positive
Stem cell
T cell
Internal medicine
Medicine
Transplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations